The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

The agency is proposing that device manufacturers improve their testing to including larger, more diverse sample sizes.

The proportion of female speakers increased over time, but they remain underrepresented in procedural and other specialties.

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

TCTMD reported in-depth on the FAVOR III Europe trial, October 30, 2024, at the TCT 2024 meeting. The full manuscript was subsequently published in EuroIntervention in January 2025. The published ...

Large, practice-changing clinical trials—those presented at the big cardiology meetings—made up half of our most-read stories. But the other contenders in 2024 reflect more quotidian concerns of TCTMD ...

This month, as we wrap up 2024, our top 10 list covered quite broad ground. There were reimbursement woes and social media shifts, plus good news for the dual GIP/GLP-1 drug tirzepatide ...

In 2024, the field of heart failure continued to see emerging positive data on therapies for heart failure with preserved ejection fraction (HFpEF), transthyretin amyloidosis with cardiomyopathy (ATTR ...